A new study led by UAB Comprehensive Diabetes Center Associate Scientist Fernando Bril, M.D., provides the first evidence that MASLD prevalence is beginning to decrease in adults with diabetes in the U.S. for the first time in decades. However, this good news is overshadowed by the significant increase observed in liver fibrosis.

A recent study authored by UAB researchers in the departments of Neurology, Medicine, and Epidemiology analyzed a decade of data to reveal that lack of access to stroke-related clinical trials may limit access to innovative treatments in geographic regions with high stroke burdens. Stroke is a leading cause of death and disability, affecting more than 795,000 people annually, with age-adjusted mortality rates varying widely by state.

After a national search, Mark Dransfield, M.D., has been appointed chair of the UAB Department of Medicine, effective Sept. 1, 2025.

In the face of a bacterium that easily resists common antibiotics, members of UAB established testing to identify it in human disease. Mycoplasma, that is. Mycoplasmas are the smallest free-living organisms. They can cause drug-resistant bacterial infections that target various parts of the body, including respiratory and urinary systems and genitalia. Mycoplasmas commonly cause lung infections and often require a special antibiotic to treat the bacterium. Most antibiotics weaken bacteria by penetrating their cell walls. Mycoplasmas, however, don’t have cell walls to weaken.

Heersink’s thriving start-up culture is producing creative solutions to improve health care outcomes. Academic medical centers (AMCs) are among the United States’ most active hives of biomedical innovation thanks to their often robust research enterprises. Increasingly, AMCs like the Heersink School of Medicine play a central role in another realm of innovation: the biomedical/biotech start-up space.

Meet some of Heersink’s outstanding new faculty members. Each issue, we introduce you to several of the exceptional new faculty that have joined the Heersink School of Medicine. These outstanding recruits—just a few of the many new faces we welcome to our faculty each year—bring with them a wealth of expertise, impressive research portfolios, and a commitment to excellence in shaping the future of medicine and health care.

The UAB Medicine Institute for Leadership, the flagship program of the UAB Medicine Leadership Development Office, recently celebrated the graduation of its 10th cohort.

The University of Alabama at Birmingham startup TIXiMED, Inc., has successfully completed a Phase 1 single ascending dose study of the drug TIX100 in humans, marking a key milestone in the development of a first-of-its kind oral therapy for Type 1 diabetes (T1D).

Chronic illnesses don’t take Saturdays off, and neither does the team at the UAB O’Neal Comprehensive Cancer Center Infusion Clinic. After experiencing a staggering 44 percent increase in patient encounters since 2020, this 84-bay infusion clinic turned to a dedicated team of multidisciplinary clinicians to pioneer Saturday infusion services. This highly trained team is ensuring that patients with cancer and other chronic diseases have access to critical treatments like chemotherapy and immunotherapy on the weekends, keeping them in the hands of trusted specialists and out of emergency rooms.

Twelve UAB employees recently graduated from the Emerging Leaders Series (ELS) spring 2025 leadership development program. The program, presented by the UAB Medicine Leadership Development Office (LDO), recognized its third cohort of graduates at a ceremony on June 5.

Ananda Basu, MBBS, MD, FRCP, M.D., has been appointed as an associate director of the UAB Comprehensive Diabetes Center (UCDC) and will play an integral role on the center’s leadership team.

A new study led by Ananda Basu, M.D., used novel non-radioactive, stable glucagon tracers for the first time to characterize glucagon metabolism in humans with and without Type 1 diabetes, providing tools for further exploration into pancreatic alpha cell function in both Type 1 and 2 diabetes and other metabolic disorders.

The UAB Pancreatobiliary Disease Center (PDC) hosted the second annual Hops & Hope Fair on Saturday, May 31, 2025 at Cahaba Brewing Company.

The UAB O’Neal Comprehensive Cancer Center recently announced five winners of the O’Neal Invests grant awards, two generously funded by the Breast Cancer Research Foundation of Alabama (BCRFA).

UAB Comprehensive Diabetes Center (UCDC) members and trainees will share their latest scientific findings at the world’s largest diabetes conference, the American Diabetes Association (ADA) 85th Scientific Sessions, June 20-23, at the McCormick Place Convention Center in Chicago.

Infectious Diseases faculty Bobbie Van Der Pol, Ph.D., MPH, and Olivia Van Gerwen, M.D., MPH, were recognized by the American Sexually Transmitted Diseases Association for their outstanding contributions to the field.

The UAB Marnix E. Heersink School of Medicine recognized 15 faculty members for their outstanding contributions to research, education, and clinical care at the Spring 2025 Endowed Chairs and Professorships Reception.

The UAB Heersink School of Medicine is proud to announce the recipients of the 2024/2025 Multi-PI Awards, each funded with $150,000 per year for two years. These awards recognize outstanding collaborative research efforts aimed at addressing critical health challenges.

The UAB Heersink School of Medicine is proud to announce the 19 winners of the 2025 Dean's Excellence Awards for Faculty.

The UAB Medicine Leadership Development Office recently recognized eight individuals in its sixth cohort of Sharing Authentically to Inspire and Lead (SAIL). The spring 2025 graduates were honored at a ceremony on April 8.